RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea.
HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.
CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
Kantum Diagnostics, Inc., doing business as Kantum Bio, develops therapeutic and diagniostics test for acute kidney injury (AKI). The company develops lead therapeutic development candidate, KB-1801 for the prophylaxis and treatment of AKI along with Uridine diphosphate glucose (UDP-G) diagnostic test to enable early diagnosis of patients at risk for AKI. The company was incorporated in 2016 and is headquartered in Concord, New Hampshire.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
The company intends to use the funds to finance the development of its first product.France-based medical device company focused on innovative technologies in the cardiovascular space
HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.
Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
Antag Therapeutics is a biotechnology company developing metabolic and anti-obesity therapeutic drugs. It offers the development of peptide-based GIP receptor antagonists in order to monitor dietary-related metabolic diseases through the infusion to decrease blood flow and lipid uptake in adipose tissue.
Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americans currently suffering from this disease.
AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
Kantum Diagnostics, Inc., doing business as Kantum Bio, develops therapeutic and diagniostics test for acute kidney injury (AKI). The company develops lead therapeutic development candidate, KB-1801 for the prophylaxis and treatment of AKI along with Uridine diphosphate glucose (UDP-G) diagnostic test to enable early diagnosis of patients at risk for AKI. The company was incorporated in 2016 and is headquartered in Concord, New Hampshire.
HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.
CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
Renovacor is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease. Renovacor’s lead program is a recombinant adeno-associated virus (AAV)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associated athanogene 3 (BAG3) gene. Dilated cardiomyopathy is a condition affecting over 3 million patients in the US and growing steadily. Many patients develop DCM due to ischemic heart disease. Recently subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM. One of these specific genes is the BAG3 gene. The prevalence of disease‑causing BAG3 haploinsufficiency is estimated at approximately 35,000 individuals in the United States, representing an orphan disease by FDA guidelines. It is estimated a similar number of DCM patients with BAG3 mutations exist in Europe. These patients are typically younger and progress to end-stage heart failure sooner than patients with ischemic heart disease. Currently, DCM patients with a BAG3 mutation are treated with standard of care for heart failure. Despite improvements in pharmacotherapy and care, the five‑year survival of a patient with DCM is only 50%. The development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent the progression of disease in this otherwise healthy population of young adults.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy. The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. It monitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration. Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reduce healthcare costs. G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States.
Antag Therapeutics is a biotechnology company developing metabolic and anti-obesity therapeutic drugs. It offers the development of peptide-based GIP receptor antagonists in order to monitor dietary-related metabolic diseases through the infusion to decrease blood flow and lipid uptake in adipose tissue.
Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.
Mellitus develops a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis, and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarker called Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts.
CellAegis Devices offers autoRIC, an automated non-invasive device that provides point-of-care delivery of remote ischemic conditioning. The Company offers automated medical devices for the treatment of patients in the ambulance and emergency room. CellAegis Devices serves customers in Canada and the United States.
Nido Surgical, Inc. is a medical device company founded in 2014 and located in Needham, Massachusetts. The company focuses on developing innovative surgical instruments for heart surgery, specifically through its flagship product, SEPIA. This Epicardial Ablation Solution is designed to address cardiac arrhythmias and facilitates video-endoscopic trans-cardiac surgical repairs within the beating heart. By enabling access through small incisions in the chest and heart wall, Nido's technology allows physicians to perform minimally invasive procedures without the need for cardiopulmonary bypass, enhancing surgical efficiency and patient recovery.
Aeromics is a clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke. A paradigm shift in its understanding of water physiology was the discovery aquaporins, proteins that form water channels to allow water into and out of cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the vital role of aquaporins in maintaining water homeostasis and its implications in various disease states, therapeutic agents targeting aquaporins have until now remained elusive. Aeromics’ drug candidate, AER-271, targets aquaporin-4 (AQP4), the primary water channel in the brain, and has best-in-class credentials for acute intravenous therapy for stroke-related cerebral edema (CE).
The company intends to use the funds to finance the development of its first product.France-based medical device company focused on innovative technologies in the cardiovascular space
Gila Therapeutics is a clinical-stage pharmaceutical company developing a therapy for obesity. Using novel routes of administration, the company develops and commercializes medicines for metabolic diseases and targets a pathway to treat obesity by increasing fullness, decreasing caloric intake, and producing weight loss.
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function.
Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine. The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer.
Viridian Therapeutics provides treatments for patients with diseases that are underserved by therapies. They develops product candidates to treat patients who suffer from thyroid eye disease, a debilitating orphan disease, and early-stage programs focused on targets and indications.
Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation. The company's medical drugs develop treatments for atrial fibrillation which is the most common type of cardiac arrhythmia by following the concept of inhibiting a type of ion channel in heart cells that is involved in generating the electrical signals that regulate the heart's rhythm, providing consumers with chronic treatment to prevent the recurrence of AF and maintain normal heart rhythm.
Ischemia Care operates as an artificial intelligence company specializing in diagnostic blood tests for stroke and atrial fibrillation. It utilizes blood testing for stroke patients as a clinical workflow tool to improve patient outcomes and reduce hospital costs, by empowering clinicians with new information. A simple blood test for cause could stratify patients by cause to ensure the appropriate treatment pathways are adopted to prevent recurrence, resulting in better outcomes. Ischemia Care was established in 2009 and is headquartered in Oxford, Ohio, United States.
Viridian Therapeutics provides treatments for patients with diseases that are underserved by therapies. They develops product candidates to treat patients who suffer from thyroid eye disease, a debilitating orphan disease, and early-stage programs focused on targets and indications.
InfoBionic transforms the efficiency and the economics of ambulatory remote patient monitoring processes and cardiac diagnostic services by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. It has developed the MoMe System, a remote patient monitoring platform initially focused on cardiac arrhythmia detection, to improve clinical efficiency and patient care with any time, anywhere access to patient data.
ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke. ZZ Biotech was formed in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein, activated Protein C (APC). The major unwanted side effect of APC is bleeding, which limits its pharmacologic dosing in man. 3K3A-APC has markedly reduced anticoagulant activity, but preserved cell-protective and anti-inflammatory activities compared to wild-type APC. In animal models of stroke 3K3A-APC has shown an advantage over wild-type APC in enhanced efficacy and reduced risk for bleeding. Additionally, the combination of 3K3A-APC and tissue Plasminogen Activator (tPA) provides benefits well beyond those found with either agent alone. ZZ Biotech is currently recruiting patients in a multicenter Phase 2 clinical trial of 3K3A-APC in patients suffering from acute ischemic stroke. The study is being supported by the National Institutes of Health through a pair of NeuroNEXT grants. The Phase 2 study is to evaluate safety, tolerability and activity of ZZ Biotech’s 3K3A-APC when given after tissue plasminogen activator (tPA), mechanical thrombectomy, or both, in patients who have experienced moderate to severe ischemic stroke.
Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylurea receptor. The company was founded in 2004 and is based in New York, New York.
Apama Medical is a privately-held medical device company focused on the rapidly growing electrophysiology (EP) market.
BioKier is an early-stage pharmaceutical company that develops drugs for diabetes and related disorders. It offers oral pills for the treatment of type 2 diabetes, as well as for metabolic syndrome and obesity conditions. It was incorporated in 2008 and is based in Chapel Hill, North Carolina
Zumbro Discovery, Inc. is developing a novel natriuretic peptide, MANP, for the treatment of resistant hypertension for which there is an unmet medical need for a syndrome which increases risk for heart failure, myocardial infarction, stroke and kidney disease. MANP was discovered at the Mayo Clinic and is soon entering first in human studies.
DecImmune Therapeutics, Inc., a biotechnology company, manufactures drugs for inflammation and autoimmunity. The company was incorporated in 2001 and is based in Boston, Massachusetts.
Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and oncology. Using two proprietary technologies, Laurantis is developing first-in-class products for commercially and medically significant niche indications in these areas. Laurantis was formed in December 2010 through a merger of the Finnish drug development companies Oy Lx Therapies Ltd and BioCis Pharma Oy.
Herantis Pharma A pharmaceutical company targeting unmet clinical needs.
InfoBionic transforms the efficiency and the economics of ambulatory remote patient monitoring processes and cardiac diagnostic services by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. It has developed the MoMe System, a remote patient monitoring platform initially focused on cardiac arrhythmia detection, to improve clinical efficiency and patient care with any time, anywhere access to patient data.
Viridian Therapeutics provides treatments for patients with diseases that are underserved by therapies. They develops product candidates to treat patients who suffer from thyroid eye disease, a debilitating orphan disease, and early-stage programs focused on targets and indications.
VGS develops innovative solutions to improve the outcome of bypass surgery and patients’ quality of life. VEST, the company’s leading product, is designed for use in Coronary Artery Bypass Grafting, to mitigate disease progression in venous bypass grafts and improve their long term performance.
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Apama Medical is a privately-held medical device company focused on the rapidly growing electrophysiology (EP) market.
Provasculon was founded to exploit the discovery by Richard Lee, MD, a cardiologist at Brigham and Women's Hospital and Associate Professor at Harvard Medical School, and Vincent Segers, MD, a researcher at Brigham and Women's Hospital, of novel forms of the growth factor Stromal Cell-Derived Factor-1 (SDF-1).
Aggamin is an early-stage biotechnology company founded in early 2010 to develop and commercialize therapies for a variety of vascular diseases. The lead program is focused on preeclampsia — a currently untreatable disease affecting 5% of pregnancies with an annual cost to the U.S health care system of $10 billion. Lead product is an extracorporeal device for preeclampsia that reduces circulating pathogenic proteins to improve maternal and fetal health. The company objectives are to manufacture and commercialize the preeclampsia device as a safe first-in-class treatment for preeclampsia that will control maternal symptoms and extend pregnancy, thus improving both maternal and neonatal outcomes.
CORIDEA is an idea generator, technology incubator and consulting firm that applies established technologies to new targets in the cardio-renal and cardio-pulmonary fields. Since its inception in 2003, Coridea has launched six startup companies including Ardian, CHF Solutions, and Respicardia (formerly, Cardiac Concepts). The $800 MM acquisition of Ardian by Medtronic marked the highest-priced venture capital-backed pre-revenue medical device acquisition to date. With 65 U.S. patents licensed by companies such as Evalve, Zoll Medical, Nephros, and PLC Medical; over $150 million in venture capital financing; and the invention of 2011 Edison Award-winning Symplicity® Catheter System™, Coridea is a leader in medical device innovation.
NuPulse is a medical device company that develops technology to treat patients with heart failure. The device, which requires minimally invasive surgery, provides patients an alternative to medical therapy. NuPulse has a strategic and financial partnership with one of the heart failure companies in the world. NuPulse’s founders have extensive clinical, engineering, and life science experience, which will allow them, along with their strategic partner and Broadview Ventures, to alter the paradigm for the treatment of heart failure. The iVAS medical device (ambulatory counterpulsation) by NuPulseCV is being evaluated through a clinical trial as an option for patients who have advanced heart failure and who are no longer benefiting from guideline-directed medical therapies. The iVAS is a less invasive option that may help address heart failure symptoms (NYHA III and IV), which may allow a heart failure patient to return to daily activities. NuPulse was formed in 2010 and is headquartered in Raleigh, North Carolina, United States.
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. The company was founded in 2005 and is headquartered in Los Angeles, California.
CellAegis Devices offers autoRIC, an automated non-invasive device that provides point-of-care delivery of remote ischemic conditioning. The Company offers automated medical devices for the treatment of patients in the ambulance and emergency room. CellAegis Devices serves customers in Canada and the United States.
i3 was created in collaboration with the Massachusetts General Hospital/Harvard Medical School (MGH) and the Technical University of Munich (TUMS) to commercialize novel Cardiovascular Imaging Technologies. i3's founders are dedicated to the advancement of Biological Imaging Modalities relating to the early detection of Coronary Artery Disease and post-interventional therapeutic viability.
Allosteros
Seed Round in 2010
Allosteros Therapeutics Inc. engages in discovery and development of breakthrough small molecule drugs that target allosteric sites on key proteins in disease pathways. Allosteros Therapeutics Inc. was incorporated in 2009 and is based in Palo Alto, California.
VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNova’s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.
Viridian Therapeutics provides treatments for patients with diseases that are underserved by therapies. They develops product candidates to treat patients who suffer from thyroid eye disease, a debilitating orphan disease, and early-stage programs focused on targets and indications.
CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).